Group A Streptococcus virulence and host factors in two toddlers with rheumatic fever following toxic shock syndrome

International Journal of Infectious Diseases

Volumn 14, Issue 5, 2010, Pages

  Smeesters, Pierre Robert ^a,b   Drèze, Pierre Alexandre ^a   Perez Morga, David ^a   Biarent, Dominique ^b   Van Melderen, Laurence ^a   Vergison, Anne ^b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

Bacterial virulence; Bacteriophage; Group A Streptococcus; Host factors; Rheumatic fever; Streptococcus pyogenes; Toxic shock syndrome

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BENZATHINE PENICILLIN; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DIGOXIN; DOPAMINE; ERYTHROMYCIN; HLA DQB1 ANTIGEN; HOST FACTOR; IMMUNOGLOBULIN; PENICILLIN G; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM; HLA DQ ANTIGEN; VIRULENCE FACTOR;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; CASE REPORT; CHILD; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GROUP A STREPTOCOCCAL INFECTION; HUMAN; INFECTION SENSITIVITY; MALE; MONARTHRITIS; POLYARTHRITIS; PRESCHOOL CHILD; RHEUMATIC FEVER; STREPTOCOCCUS GROUP A; SUBCUTANEOUS NODULE; TODDLER; TOXIC SHOCK SYNDROME; CHEMISTRY; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFANT; MICROBIOLOGY; PATHOGENICITY; POLYMERASE CHAIN REACTION; SEPTIC SHOCK; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

FEMALE; HLA-DQ ANTIGENS; HOST-PATHOGEN INTERACTIONS; HUMANS; INFANT; MALE; POLYMERASE CHAIN REACTION; RHEUMATIC FEVER; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; VIRULENCE FACTORS;

EID: 77955872852     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.06.025     Document Type: Article

References (37)

1. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5:685-694.
2. Carapetis J.R., McDonald M., Wilson N.J. Acute rheumatic fever. Lancet 2005, 366:155-168.
3. Carapetis J.R. Rheumatic heart disease in developing countries. N Engl J Med 2007, 357:439-441.
4. Bisno A.L., Brito M.O., Collins C.M. Molecular basis of group A streptococcal virulence. Lancet Infect Dis 2003, 3:191-200.
5. Jones T.D. Diagnosis of rheumatic fever. JAMA 1944, 126:481-484.
6. Tani L.Y., Veasy L.G., Minich L.L., Shaddy R.E. Rheumatic fever in children under 5 years. Pediatrics 2004, 114:906.
7. Zaman M.M., Rouf M.A., Haque S., Khan L.R., Chowdhury N.A., Razzaque S.A., et al. Does rheumatic fever occur usually between the ages of 5 and 15 years?. Int J Cardiol 1998, 66:17-21.
8. The WHO Young Infants Study Group. Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. Pediatr Infect Dis J, 1999; 18:S17-22.
9. Facklam R., Beall B., Efstratiou A., Fischetti V., Johnson D., Kaplan E., et al. emm typing and validation of provisional M types for group A streptococci. Emerg Infect Dis 1999, 5:247-253.
10. Stollerman G.H. Rheumatic fever in the 21st century. Clin Infect Dis 2001, 33:806-814.
11. Vlaminckx B.J., Schuren F.H., Montijn R.C., Caspers M.P., Fluit A.C., Wannet W.J., et al. Determination of the relationship between group A streptococcal genome content, M type, and toxic shock syndrome by a mixed genome microarray. Infect Immun 2007, 75:2603-2611.
12. O'Loughlin R.E., Roberson A., Cieslak P.R., Lynfield R., Gershman K., Craig A., et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007, 45:853-862.
13. Banks D.J., Lei B., Musser J.M. Prophage induction and expression of prophage-encoded virulence factors in group A Streptococcus serotype M3 strain MGAS315. Infect Immun 2003, 71:7079-7086.
14. Proft T., Fraser J.D. Streptococcal superantigens. Chem Immunol Allergy 2007, 93:1-23.
15. Tart A.H., Walker M.J., Musser J.M. New understanding of the group A Streptococcus pathogenesis cycle. Trends Microbiol 2007, 15:318-325.
16. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA, 1993; 269:390-1.
17. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. Guidelines for the diagnosis of rheumatic fever. Jones criteria, 1992 update. JAMA, 1992; 268:2069-73.
18. Olerup O., Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992, 39:225-235.
19. Smeesters P.R., Vergison A., Campos D., de Aguiar E., Deyi V.Y., Van Melderen L. Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape. PLoS ONE 2006, 1:e10.
20. Green N.M., Beres S.B., Graviss E.A., Allison J.E., McGeer A.J., Vuopio-Varkila J., et al. Genetic diversity among type emm28 group A Streptococcus strains causing invasive infections and pharyngitis. J Clin Microbiol 2005, 43:4083-4091.
21. Vlaminckx B.J., Mascini E.M., Schellekens J., Schouls L.M., Paauw A., Fluit A.C., et al. Site-specific manifestations of invasive group A streptococcal disease: type distribution and corresponding patterns of virulence determinants. J Clin Microbiol 2003, 41:4941-4949.
22. Proft T., Moffatt S.L., Berkahn C.J., Fraser J.D. Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med 1999, 189:89-102.
23. Vlaminckx B.J., Schuren F.H., Montijn R.C., Caspers M.P., Beitsma M.M., Wannet W.J., et al. Dynamics in prophage content of invasive and noninvasive M1 and M28 Streptococcus pyogenes isolates in the Netherlands from 1959 to 1996. Infect Immun 2007, 75:3673-3679.
24. Darenberg J., Luca-Harari B., Jasir A., Sandgren A., Pettersson H., Schalen C., et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 2007, 45:450-458.
25. Bidet P., Courroux C., Salgueiro C., Carol A., Mariani-Kurkdjian P., Bonacorsi S., et al. Molecular epidemiology of the sil streptococcal invasive locus in group A streptococci causing invasive infections in French children. J Clin Microbiol 2007, 45:2002-2004.
26. Johnson D.R., Wotton J.T., Shet A., Kaplan E.L. A comparison of group A streptococci from invasive and uncomplicated infections: are virulent clones responsible for serious streptococcal infections?. J Infect Dis 2002, 185:1586-1595.
27. McMillan D.J., Beiko R.G., Geffers R., Buer J., Schouls L.M., Vlaminckx B.J., et al. Genes for the majority of group A streptococcal virulence factors and extracellular surface proteins do not confer an increased propensity to cause invasive disease. Clin Infect Dis 2006, 43:884-891.
28. Rogers S., Commons R., Danchin M.H., Selvaraj G., Kelpie L., Curtis N., et al. Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group A Streptococcus infections. J Infect Dis 2007, 195:1625-1633.
29. Pahlman L.I., Olin A.I., Darenberg J., Morgelin M., Kotb M., Herwald H., et al. Soluble M1 protein of Streptococcus pyogenes triggers potent T cell activation. Cell Microbiol 2007.
30. Aminov R.I., Mackie R.I. Evolution and ecology of antibiotic resistance genes. FEMS Microbiol Lett 2007, 271:147-161.
31. Sumby P., Porcella S.F., Madrigal A.G., Barbian K.D., Virtaneva K., Ricklefs S.M., et al. Evolutionary origin and emergence of a highly successful clone of serotype M1 group A Streptococcus involved multiple horizontal gene transfer events. J Infect Dis 2005, 192:771-782.
32. Sitkiewicz I., Nagiec M.J., Sumby P., Butler S.D., Cywes-Bentley C., Musser J.M. Emergence of a bacterial clone with enhanced virulence by acquisition of a phage encoding a secreted phospholipase A2. Proc Natl Acad Sci U S A 2006, 103:16009-16014.
33. Banks D.J., Beres S.B., Musser J.M. The fundamental contribution of phages to GAS evolution, genome diversification and strain emergence. Trends Microbiol 2002, 10:515-521.
34. Broudy T.B., Fischetti V.A. In vivo lysogenic conversion of Tox(-) Streptococcus pyogenes to Tox(+) with lysogenic streptococci or free phage. Infect Immun 2003, 71:3782-3786.
35. Kotb M., Norrby-Teglund A., McGeer A., El-Sherbini H., Dorak M.T., Khurshid A., et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002, 8:1398-1404.
36. Imanishi K., Igarashi H., Uchiyama T. Relative abilities of distinct isotypes of human major histocompatibility complex class II molecules to bind streptococcal pyrogenic exotoxin types A and B. Infect Immun 1992, 60:5025-5029.
37. Abdeltawab N.F., Aziz R.K., Kansal R., Rowe S.L., Su Y., Gardner L., et al. An unbiased systems genetics approach to mapping genetic loci modulating susceptibility to severe streptococcal sepsis. PLoS Pathog 2008, 4:e1000042.